Use of omalizumab in the treatment of hypocomplementemic urticarial vasculitis

Dermatol Ther. 2020 Mar;33(2):e13237. doi: 10.1111/dth.13237. Epub 2020 Feb 17.
No abstract available

Publication types

  • Letter

MeSH terms

  • Humans
  • Omalizumab / therapeutic use
  • Urticaria* / diagnosis
  • Urticaria* / drug therapy
  • Vasculitis* / diagnosis
  • Vasculitis* / drug therapy
  • Vasculitis, Leukocytoclastic, Cutaneous* / diagnosis
  • Vasculitis, Leukocytoclastic, Cutaneous* / drug therapy

Substances

  • Omalizumab